Clinical Trial

Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy. Characterized by their rich bioactive components, absence of tumorigenic risk, and high safety profile, hUCMSC-Exos represent a promising approach for hair regeneration. This study aims to evaluate the safety and efficacy of hUCMSC-Exos combined with automated microneedle delivery for treating AGA. By utilizing innovative lyophilization technology to maintain exosomal bioactivity and employing precision microneedle systems for enhanced delivery, this research seeks to provide a new generation solution for androgenic alopecia treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-20.
Trial Details
NCT Number NCT07373054
Lead Sponsor Fujian Medical University Union Hospital
Conditions Androgenic Alopecia
Enrollment 18 participants
Start Date 2025-11-06
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-30